David Ricks; Chairman of the Board, President, Chief Executive Officer; Eli Lilly and Co Lucas Montarce; Executive Vice President and Chief Financial Officer; Eli Lilly and Co Daniel Skovronsky; Chief ...

David Ricks; Chairman of the Board, President, Chief Executive Officer; Eli Lilly and Co Lucas Montarce; Executive Vice President and Chief Financial Officer; Eli Lilly and Co Daniel Skovronsky ...

Eli Lilly and Co (NYSE:LLY) reported a 32% increase in full ... or can it be achieved with the current trajectory? A: Lucas Montarce, Executive Vice President and Chief Financial Officer, stated that ...

Thank you for joining us for Eli Lilly and Company's Q4 2024 ... chief scientific officer and president of Lilly Immunology; Lucas Montarce, chief financial officer; Anne White, president of ...

Operator Ladies and gentlemen, thank you for standing by and welcome to the Lilly Q4 2024 earnings call. [Operator instructions] I would now like to turn the conference over to your host, Mike Czapar, ...

Good morning, thank you for joining us for Eli Lilly and Company's Q4 2024 ... Chief Scientific Officer and President of Lilly Immunology; Lucas Montarce, Chief Financial Officer; Anne White ...

CFO Lucas Montarce reported a gross margin increase ... were acknowledged but framed as opportunities to showcase product differentiation. Eli Lilly ended 2024 on a strong note, with 45% revenue ...

Eli Lilly’s profit doubled in the fourth quarter, propelled by its hot-selling diabetes and obesity treatments, and the drugmaker came out with a mostly better-than-expected 2025 forecast.